ERZOFRI Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Erzofri, and when can generic versions of Erzofri launch?

Erzofri is a drug marketed by Luye Innomind Pharma and is included in one NDA. There is one patent protecting this drug.

This drug has seven patent family members in six countries.

The generic ingredient in ERZOFRI is paliperidone palmitate. There are thirty-eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the paliperidone palmitate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Erzofri

A generic version of ERZOFRI was approved as paliperidone palmitate by TEVA PHARMS USA on July 6^th, 2021.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for ERZOFRI?
What are the global sales for ERZOFRI?
What is Average Wholesale Price for ERZOFRI?

Summary for ERZOFRI

International Patents:	7
US Patents:	1
Applicants:	1
NDAs:	1
DailyMed Link:	ERZOFRI at DailyMed

Drug patent expirations by year for ERZOFRI

US Patents and Regulatory Information for ERZOFRI

ERZOFRI is protected by two US patents.

Patents protecting ERZOFRI

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S)

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S)

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-001	Jul 26, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-004	Jul 26, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-002	Jul 26, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Luye Innomind Pharma	ERZOFRI	paliperidone palmitate	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	216352-003	Jul 26, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for ERZOFRI

See the table below for patents covering ERZOFRI around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Canada	3077224	SCHEMA POSOLOGIQUE D'UNE SUSPENSION INJECTABLE A LIBERATION PROLONGEE DE PALMITATE DE PALIPERIDONE (DOSAGE REGIMEN OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION)	⤷ Sign Up
European Patent Office	3700531	SCHÉMA POSOLOGIQUE D'UNE SUSPENSION INJECTABLE À LIBÉRATION PROLONGÉE DE PALMITATE DE PALIPÉRIDONE (DOSAGE REGIMEN OF PALIPERIDONE PALMITATE EXTENDED-RELEASE INJECTABLE SUSPENSION)	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2019084501		⤷ Sign Up
Japan	7337080		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for ERZOFRI

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0904081	11C0035	France	⤷ Sign Up	PRODUCT NAME: PALMITATE DE PALIPERIDONE; REGISTRATION NO/DATE: EU/1/11/672/001 20110304
0368388	SPC/GB07/065	United Kingdom	⤷ Sign Up	PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021
0904081	SPC/GB11/044	United Kingdom	⤷ Sign Up	PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304
0904081	2011/021	Ireland	⤷ Sign Up	PRODUCT NAME: PALIPERIDONE PALMITATE ESTER; REGISTRATION NO/DATE: EU/1/11/672/001-006 20110304
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

AI Research Assistant

Questions you can ask:

Summary for ERZOFRI

Patents protecting ERZOFRI

Make Better Decisions: Try a trial or see plans & pricing